Trust Signals
Key Takeaways
- Tesamorelin is the only cutting-related peptide with FDA approval and Phase III RCT data for fat reduction, specifically visceral fat in HIV lipodystrophy.
- CJC-1295 without DAC (Mod GRF 1-29) has a half-life near 30 minutes; the DAC version extends this to roughly 6 to 8 days, making them functionally different compounds for pulsatile GH protocols.
- GHRP-6 stimulates ghrelin receptors and increases appetite, which directly conflicts with cutting goals. Ipamorelin does not carry this effect at standard doses in animal studies.
- AOD-9604 completed Phase II human trials with mixed results; Phase IIb did not meet its primary fat-loss endpoint. It is not FDA-approved for any indication.
- Semaglutide outperforms every research peptide on this list for total fat loss in human clinical trials, by a large margin. Any honest comparison must say so.
What Are the Best Peptides for Cutting? (Direct Answer)
The best peptides for cutting, ranked by quality of human evidence, are: Tesamorelin (only one with approved Phase III data), followed by CJC-1295 combined with Ipamorelin for GH pulse amplification, and AOD-9604 for direct lipolysis signaling. BPC-157 supports recovery during cuts but does not burn fat. All require a calorie deficit to work.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: What Each Peptide Can Actually Claim
- How Cutting Peptides Work: Mechanism With Real Numbers
- The Ranked List: Which Peptides for Cutting and Why
- What Most Pages Get Wrong About Cutting Peptides
- Chemistry Behind the Rules: Why Storage and Timing Matter
- Honest Head-to-Head: Peptides vs. Real Alternatives
- Operational Guide: COA Literacy, Dosing Units, Reconstitution
- FAQ
- Sources
Evidence Ledger: What Each Peptide Can Actually Claim
| Peptide | Best Evidence Type | Effect on Fat | Confidence | Key Caveat |
|---|---|---|---|---|
| Tesamorelin | Phase III human RCT (HIV lipodystrophy) | Reduces visceral adipose tissue | Moderate (limited to specific population) | Approved only for HIV lipodystrophy; healthy population data is sparse |
| CJC-1295 plus Ipamorelin | Small human PK/PD studies; animal fat-loss data | Increases GH pulse amplitude; indirect fat mobilization | Low | No RCT in healthy humans for body composition as primary endpoint |
| AOD-9604 | Phase II human trials (mixed results) | Trend toward fat loss in Phase IIa; Phase IIb non-significant | Low | Development program halted; not approved for any indication |
| Ipamorelin alone | Animal studies; limited human PK data | GH secretagogue; indirect lipolysis | Very Low | Most human data is pharmacokinetic, not body-composition outcomes |
| GHRP-2 | Small human studies (GH secretion) | GH elevation; modest cortisol/prolactin elevation | Very Low | Cortisol elevation may oppose fat loss at high doses |
| BPC-157 | Animal studies only | No direct fat-loss effect demonstrated | Very Low | No human RCTs exist for any BPC-157 indication |
| Hexarelin | Small human studies (GH, cardiac) | GH secretagogue; also stimulates ghrelin receptor | Very Low | Rapid desensitization observed; appetite stimulation concern |
How Cutting Peptides Work: Mechanism With Real Numbers
Growth hormone and lipolysis. The common thread for most cutting peptides is growth hormone (GH). GH activates hormone-sensitive lipase in adipocytes, increasing free fatty acid release. GH also promotes fatty acid oxidation and has an anti-lipogenic effect partly through reducing lipoprotein lipase activity in fat tissue. These are well-established mechanisms from metabolic physiology; the debate is how much a peptide-driven GH pulse translates to meaningful fat loss in a person who is already in a caloric deficit.
CJC-1295 pharmacokinetics. A 2006 human study by Teichman et al. (published in the Journal of Clinical Endocrinology and Metabolism) tested single doses of CJC-1295 with DAC and found mean GH levels remained elevated for up to 6 days at doses between 30 and 60 mcg/kg, with a terminal half-life estimated at roughly 6 to 8 days. This is the source of the "weekly dosing" claim. CJC-1295 without DAC (Mod GRF 1-29) does not have albumin binding, so the half-life falls to approximately 30 minutes, similar to native GHRH.
Ipamorelin selectivity. Ipamorelin is a pentapeptide GHRP that binds the ghrelin receptor (GHS-R1a) but shows less activation of the ACTH-cortisol and prolactin axes than GHRP-2 or GHRP-6 in animal studies. The Raun et al. 1998 paper in the European Journal of Endocrinology established its selectivity profile in rats. This selectivity is frequently cited but the human translation is not confirmed at the same resolution.
AOD-9604 mechanism. AOD-9604 is a synthetic fragment corresponding to amino acids 177 to 191 of the human growth hormone sequence, with an additional tyrosine at position 177. The fragment retains the beta-3 adrenergic-like lipolytic activity of full GH in fat tissue without binding the GH receptor, which means it does not cause IGF-1 elevation or insulin resistance in animal models. This mechanistic separation is real and documented in rodent studies, but the Phase IIb human trials did not confirm that this translates to clinically significant fat loss at tested doses.
Tesamorelin mechanism. Tesamorelin is a full-length GHRH analogue (44 amino acids) with a trans-3-hexenoic acid modification at the N-terminus that improves plasma stability. In the pivotal LIPO-010 and LIPO-011 trials, subcutaneous tesamorelin 2 mg daily reduced visceral adipose tissue area by roughly 15 to 18 percent compared to placebo in HIV-positive adults with lipodystrophy, as measured by CT scan. These are the highest-quality fat-loss data available for any GHRH analogue in humans.
What the mechanism does NOT prove. Elevated GH pulses in young, healthy people already produce GH levels far above baseline during deep sleep and post-exercise. Adding a GH secretagogue on top of normal physiology may produce less marginal benefit than the animal data suggests. Receptor desensitization is also a real concern with chronic GHRP use.
The Ranked List: Which Peptides for Cutting and Why
1. Tesamorelin. Best evidence. The only GHRH-class peptide with Phase III RCT data for fat reduction. Use is restricted by regulatory status (FDA-approved only for HIV lipodystrophy; off-label use requires a prescribing clinician). Dose used in trials: 2 mg subcutaneously daily.
2. CJC-1295 without DAC plus Ipamorelin. The most rational combination for pulsatile GH support during a cut. Without DAC preserves the natural pulsatile pattern. Ipamorelin adds ghrelin-receptor stimulation without the appetite-driving profile of GHRP-6. Common research doses: 100 to 300 mcg of each, injected together before sleep. Confidence remains low due to absence of body-composition RCTs in healthy adults.
3. AOD-9604. Mechanistically interesting because it targets lipolysis without IGF-1 elevation. Human clinical program exists (distinguishing it from most gray-market peptides). However, the pivotal efficacy trial failed its primary endpoint. Use only with clear-eyed expectations.
4. Ipamorelin alone. Reasonable for someone who wants GH pulse support without a GHRH component. Lower GH amplification than the combination. Relevant if CJC-1295 is unavailable or unwanted. Evidence base is thinner.
5. BPC-157. Not a fat-loss peptide. Included on many cutting lists because aggressive cuts and high-volume training increase injury risk. If recovery support is the goal during a cut, BPC-157's animal-based injury-repair data makes it worth knowing about. Do not expect direct fat loss.
What Most Pages Get Wrong About Cutting Peptides
Confusing bioavailability with activity. Peptides are not orally bioavailable in meaningful quantities because gastric proteases cleave them before absorption. This is why injectable routes are standard in research. Any oral "peptide supplement" claiming to raise GH or burn fat the same way as the injectable forms has not cleared the basic biology hurdle. The peptide bond is destroyed before the compound reaches systemic circulation.
Ignoring purity and source reality. Independent testing of gray-market peptide vials sold as research chemicals has repeatedly found purity below 90 percent, incorrect molecular weights, and in some cases unrelated peptides. A certificate of analysis from the same vendor who sells you the compound is not independent verification. This is the single most overlooked variable in community-based cutting protocols.
Assuming animal lipolysis data scales linearly to humans. Rodent fat metabolism, GH receptor density, and metabolic rate differ substantially from humans. AOD-9604 reduced fat mass significantly in obese mice. The human trials produced a much weaker signal. This is the standard pattern in metabolic pharmacology. Rodent data is hypothesis-generating, not dose-justifying.
Stacking without considering desensitization. Chronic GHRP administration in animal and limited human data produces GHS-R1a desensitization. Many community protocols use 5-day-on, 2-day-off cycles to attempt to preserve receptor sensitivity. This is a reasonable precaution, but the optimal cycle structure in humans is not established by controlled data.
Chemistry Behind the Rules: Why Storage and Timing Matter
Why lyophilized peptides degrade. Peptide bonds are susceptible to hydrolysis. In the lyophilized (freeze-dried) state, water activity is extremely low, which dramatically slows hydrolysis. Once reconstituted in aqueous solution, the hydrolysis rate increases with temperature and with extremes of pH. This is why refrigerated storage after reconstitution is required, not optional. Light exposure accelerates oxidation of methionine and tryptophan residues present in some peptides.
Why bacteriostatic water, not sterile water. Sterile water contains no preservative. If you draw from the same vial more than once, microbial contamination accumulates. Bacteriostatic water contains 0.9 percent benzyl alcohol, which inhibits bacterial growth and extends multi-use vial safety. Using sterile water for a multi-dose vial is a contamination risk that commodity pages never explain.
Why inject before sleep. Endogenous GH is secreted in pulses, with the largest pulse occurring in slow-wave sleep. Injecting a GHRH or GHRP analogue 30 to 60 minutes before sleep is intended to amplify this existing pulse rather than create an out-of-phase signal. This timing rationale comes from basic GH physiology, not a controlled cutting trial. Eating carbohydrates close to the injection raises insulin and blunts GH response, which is why a 2 to 3 hour fast before injection is commonly recommended. The underlying mechanism, insulin suppressing somatostatin, is well established.
Why heat destroys potency. Elevated temperature increases molecular kinetic energy and therefore the rate of all degradation reactions. A peptide vial left at room temperature for several weeks may retain its visual appearance while losing 20 to 50 percent of active compound through hydrolysis and oxidation. There is no reliable visual indicator of chemical degradation. This is a failure mode that product sellers have no incentive to advertise.
Honest Head-to-Head: Peptides vs. Real Alternatives
| Compound | Mechanism Class | Human RCT Evidence for Fat Loss | Approval Status | Practical Fat-Loss Magnitude (Humans) | Key Risk |
|---|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 receptor agonist | Yes, Phase III (STEP-1: ~15% body weight loss, Wilding et al., NEJM 2021) | FDA-approved for obesity | Large (15% body weight over 68 weeks) | GI side effects, cost, muscle mass loss without resistance training |
| Tesamorelin | GHRH analogue | Yes, Phase III (visceral fat, HIV population) | FDA-approved (narrow indication) | Moderate visceral fat reduction in specific population | Off-label use regulatory risk; fluid retention possible |
| CJC-1295 plus Ipamorelin | GHRH plus GHRP | No body-composition RCT in healthy adults | Not approved; research use only | Unknown; likely small without deficit | Purity risk, WADA prohibition, receptor desensitization |
| AOD-9604 | GH fragment | Phase IIb failed primary endpoint | Not approved | Weak to negligible in humans | Purity risk, unclear long-term safety |
| Clenbuterol (reference) | Beta-2 adrenergic agonist | No obesity RCT; used clinically for asthma | Not approved for fat loss | Modest in context of studies; significant cardiac risk | Cardiac arrhythmia, tremor, prohibited in sport |
| Topical retinoid (tretinoin, for context) | Retinoic acid receptor agonist | Not relevant to systemic fat loss | FDA-approved (dermatology) | Not applicable | Included to illustrate evidence contrast in the peptide space |
The honest verdict. If the goal is maximum fat loss with the strongest evidence base, semaglutide wins. Peptides have a plausible niche in preserving lean mass and targeting visceral fat specifically, in populations where GH axis optimization is relevant, but no peptide on this list has demonstrated the magnitude of fat loss seen with approved GLP-1 agonists in head-to-head human data.
Operational Guide: COA Literacy, Dosing Units, Reconstitution
Reading a COA for cutting peptides. A trustworthy certificate of analysis for a research peptide should include: (1) HPLC purity percentage with the actual chromatogram trace, not just a number, (2) mass spectrometry confirming molecular weight matches the theoretical value for the stated peptide, (3) the testing laboratory name and date (not just the vendor's internal QC), (4) endotoxin testing result if injection is intended. Reject any COA that is undated, lacks the HPLC trace, or comes only from the vendor's own lab.
Reconstitution math. Standard: add bacteriostatic water to a lyophilized vial and calculate concentration. If a vial contains 5 mg of peptide and you add 2.5 mL of bacteriostatic water, concentration is 2 mg per mL (2000 mcg/mL). A 100 mcg dose from that solution requires 0.05 mL (50 microliters on an insulin syringe). Confirm your syringe markings: a 1 mL insulin syringe marked in 100 units has each unit equal to 0.01 mL. A 50-microliter draw is the 5-unit mark. This arithmetic error is the most common dosing mistake in community use.
Dosing table (research doses commonly referenced in the literature and community, not prescriptive recommendations).
| Peptide | Common Research Dose Range | Route | Timing | Frequency |
|---|---|---|---|---|
| Tesamorelin | 2 mg (trial dose) | Subcutaneous | Daily | Daily (as used in trials) |
| CJC-1295 without DAC | 100 to 300 mcg | Subcutaneous | Before sleep | Daily or 5 days on, 2 days off |
| Ipamorelin | 100 to 300 mcg | Subcutaneous | Before sleep (combined with above) | Same as CJC-1295 without DAC |
| AOD-9604 | 300 to 500 mcg (Phase IIa doses) | Subcutaneous | Morning, fasted | Daily |
| BPC-157 | 200 to 500 mcg | Subcutaneous or intramuscular | Near injured area or systemic | Daily during recovery |
What degraded product looks like. Most peptide solutions are clear and colorless. Yellow or brown discoloration suggests oxidative degradation. Cloudiness suggests either microbial contamination or protein aggregation. Both are reasons to discard the vial. A peptide that has been reconstituted and left at room temperature for more than a few days should be treated as compromised regardless of appearance, because chemical degradation precedes visible changes.
FAQ
What are the best peptides for cutting fat?
AOD-9604, CJC-1295 combined with Ipamorelin, and Tesamorelin have the strongest mechanistic basis for fat loss among research peptides. Tesamorelin is the only one with Phase III human RCT data for fat reduction; the others rely primarily on animal and small human studies.
Does AOD-9604 actually burn fat in humans?
Phase II trials in obese humans showed modest fat-loss trends at certain doses, but subsequent Phase IIb trials did not reach statistical significance for the primary endpoint. The human evidence is inconclusive. Animal data is more convincing. Treat claims of guaranteed fat loss from AOD-9604 with skepticism.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC binds albumin and has a half-life of roughly 6 to 8 days in humans, allowing weekly dosing. Without DAC (also called Mod GRF 1-29), the half-life drops to approximately 30 minutes. This matters for pulsatile GH release: without DAC more closely mimics natural GH secretion patterns.
Can peptides replace a calorie deficit for cutting?
No. No research peptide has demonstrated fat loss independent of a caloric deficit in healthy humans. GH-axis peptides shift substrate utilization toward fat oxidation and may preserve lean mass, but they do not override energy balance. Diet and training remain the primary variables.
Is Ipamorelin safer than GHRP-2 or GHRP-6 for cutting?
Ipamorelin has a more selective GH-releasing profile in animal studies, producing less cortisol and prolactin elevation than GHRP-2 or GHRP-6. GHRP-6 notably stimulates ghrelin receptors, which increases appetite, directly opposing a cutting goal. On that basis, Ipamorelin is the more sensible choice for fat-loss protocols.
What does Tesamorelin do and who is it approved for?
Tesamorelin is an FDA-approved GHRH analogue indicated for HIV-associated lipodystrophy. Phase III trials showed statistically significant reductions in visceral adipose tissue. It is not approved for general fat loss in healthy individuals, and off-label use carries regulatory and safety considerations.
How should cutting peptides be stored and reconstituted?
Lyophilized peptides should be stored at 2 to 8 degrees Celsius, away from light. Reconstitute with bacteriostatic water, not sterile water, if you plan to use the vial over multiple days. After reconstitution, most peptides degrade meaningfully within 2 to 4 weeks at refrigerator temperature. Never use if the solution is cloudy or has visible particulates.
Are cutting peptides detectable on drug tests?
WADA prohibits GH-releasing peptides including GHRPs and GHRH analogues under the S2 category (peptide hormones and growth factors). Tesamorelin, Ipamorelin, CJC-1295, and AOD-9604 fall within this category. Detection windows vary by peptide and test method. Competitive athletes should assume these compounds are prohibited.
What does BPC-157 have to do with cutting?
BPC-157 does not directly promote fat loss. Its relevance in cutting contexts is injury recovery and tendon/joint support during high-volume training or aggressive caloric restriction, which increase injury risk. Evidence is primarily animal-based; no human RCTs exist for BPC-157 in any indication.
How do cutting peptides compare to semaglutide for fat loss?
Semaglutide (GLP-1 receptor agonist) has Phase III RCT data showing roughly 15 percent body weight reduction over 68 weeks in non-diabetic obese adults (STEP-1 trial, Wilding et al., NEJM 2021). No research peptide listed here has evidence remotely close to that magnitude in healthy humans. Semaglutide wins on evidence, by a wide margin.
What purity level should a cutting peptide COA show?
Look for HPLC purity at or above 98 percent on the certificate of analysis, with mass spectrometry confirming correct molecular weight. A COA without an HPLC chromatogram trace, a dated test, and an independent lab name is not meaningful. Many gray-market peptides test below 90 percent purity or contain the wrong compound entirely.
Sources
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology. 2001;142(12):5182-5189.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. (Tesamorelin pivotal trial)
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018;6(1):45-53.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797.
- World Anti-Doping Agency. Prohibited List 2024. S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA, 2024.
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998;54(12):1316-1329. (GHRP class overview including cortisol/prolactin selectivity comparisons)
- FDA. Egrifta (tesamorelin) Prescribing Information. Theratechnologies Inc. Revised 2023.